Intellipharmaceutics International Inc. (IPCI)

[fabius]

Company Trevena is the centre point of the article.
Interesting to see how a company with no products in the market, making a 37mln usd loss (as per 10Q Sec filing), has a current mkt cap of 325Mln Usd.


This is a point to all those that are here writing about IPCI deals not having an immediate imapact on cash, revenue, profit...whatever.

I'm not saying that those analysis here proposed are not right, but I want to point out how the share price of a biotech usually tends to give very much importance to future developments.

Hope to see IPCI share price starting to reflect those future cash inflows.

Go IPCI, it's time